Beam Therapeutics Inc. (BEAM)
D
Pipeline Grade
Financial Position (from SEC Filings)
$295.0M
Cash & Equivalents
$128.5M
Quarterly Burn Rate
7 mo
Est. Cash Runway
$3,362M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-12-01 | Phase2 Readout | — |
Active Clinical Trials (8)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07373639 | A Long-term Follow-up Study in Patients Who Received BEAM-101 | OTHER | Recruiting | 50 |
| NCT06071377 | Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT) | OTHER | Recruiting | 1,000 |
| NCT06389877 | A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD) | PHASE2 | Recruiting | 106 |
| NCT05456880 | BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease | PHASE2 | Active Not Recruiting | 15 |
| NCT05885464 | A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL... | PHASE2 | Active Not Recruiting | 5 |
| NCT06735755 | A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Di... | PHASE2 | Recruiting | 36 |
| NCT07304791 | This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and P... | PHASE1 | Recruiting | 30 |
| NCT06934382 | Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma | PHASE1 | Recruiting | 33 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.